Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease: JACC Scientific Expert Panel.

Abstract

Stroke survivors carry a high risk of recurrence. Antithrombotic medications are paramount for secondary prevention and thus crucial to reduce the overall stroke burden. Appropriate antithrombotic agent selection should be based on the best understanding of the physiopathological mechanism that led to the initial ischemic injury. Antiplatelet therapy is preferred for lesions characterized by atherosclerosis and endothelial injury, whereas anticoagulant agents are favored for cardiogenic embolism and highly thrombophilic conditions. Large randomized controlled trials have provided new data to support recommendations for the evidence-based use of antiplatelet agents and anticoagulant agents after stroke. In this review, the authors cover recent trials that have altered clinical practice, cite systematic reviews and meta-analyses, review evidence-based recommendations based on older landmark trials, and indicate where there are still evidence-gaps and new trials being conducted.

• Authors: Victor J Del Brutto, Seemant Chaturvedi, Hans-Christoph Diener, Jose G Romano, Ralph L Sacco
• Journal: Journal of the American College of Cardiology (J Am Coll Cardiol) Vol. 74 Issue 6 Pg. 786-803 (08 13 2019) ISSN: 1558-3597 [Electronic] United States
• PMID: 31395130 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Chemical References

• Fibrinolytic Agents

Topics

• Fibrinolytic Agents (therapeutic use)
• Humans
• Ischemic Attack, Transient (prevention & control)
• Recurrence
• Secondary Prevention (methods)
• Stroke (prevention & control)